Moleculin Biotech, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Moleculin Biotech, Inc. (MBRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $73.19 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-18
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $0.00.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $73.19, a 343.58% increase from fiscal 2024.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $16.50, a 48.65% increase from fiscal 2023.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $11.10, a 54.49% decline from fiscal 2022.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $24.39.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $73.19 10-K · filed 2026-03-18 | |||
| 2024-12-31 | $16.50 10-K · filed 2025-03-21 | |||
| 2023-12-31 | $11.10 10-K · filed 2024-03-22 | |||
| 2022-12-31 | $24.39 10-K · filed 2023-03-22 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-24 | |||
| 2020-12-31 | $6.36 10-K · filed 2021-03-24 | |||
| 2020-09-30 | $1.06 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $1.06 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $1.82 10-K · filed 2020-03-19 | |||
| 2019-09-30 | $1.82 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | $2.49 10-K · filed 2019-02-21 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-12 | |||
| 2016-12-31 | $0.20 10-K · filed 2018-03-28 | |||
| 2016-09-30 | $0.20 10-Q · filed 2016-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |